Document is current
Any future updates will be listed below
-
Authors
Mayorca-Guiliani, Alejandro E.
Leeming, Diana Julie
Henriksen, Kim
Mortensen, Joachim Høg
Nielsen, Signe Holm
Anstee, Quentin M.
Sanyal, Arun J.
Karsdal, Morten A.
Schuppan, Detlef
- License Information
-
More Information
Article History
Received: 28 October 2024
Accepted: 15 April 2025
First Online: 10 June 2025
Competing interests
: A.E.M.-G., D.J.L., K.H., J.H.M., and M.A.K. are employees of Nordic Bioscience A/S. D.J.L., K.H., J.H.M., S.H.N., and M.A.K. are Nordic Bioscience A/S stockholders. A.J.S.: has stock options in Durect, Inversago, Tiziana, Rivus, Exhalenz, Genfit. He has served as a consultant to Intercept, Gilead, Takeda, Meck, Eli Lilly, Novo Nordisk, Astra Zeneca, Boehringer Ingelheim, Alnylam, Regeneron, Histoindex, Path AI, Pfizer, 89Bio, Altimmune, Northsea, Akero, Madrigal, Salix, Myovant, Poxel, Surrozen, Hanmi, Aligos, Promed, Zydus. His institution has received grants from Intercept, Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Echosens, Hanmi, Madrigal, Gilead, Salix, Meck, Takeda. He receives royalties from Elsevier and Wolter Kluwers. D.S.: is CMO, co-CEO/CSO for ImmuneNTech, and consults for Falk Pharma, Takeda, Boehringer-Ingelheim, Resalis, Immunic, Sanofi, Northsea Bioscirences.
